A US advisory panel has dialed back its current recommendation for routine immunization of older adults with Pfizer Inc.’s Prevnar 13 but is not proposing to entirely eliminate use of the pneumococcal 13-valent conjugate vaccine in this age group.
In a compromise vote that followed unsuccessful votes on two prior proposals, 13 of 14 members of the Advisory Committee...







